# A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

> **NCT07187115** · NA · RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 699 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)
- Persistant Atrial Fibrillation

## Interventions

- **DEVICE:** FARAPOINT Pulsed Field Ablation System
- **DEVICE:** OptiMap System (non-ablative)
- **DEVICE:** FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

## Key facts

- **NCT ID:** NCT07187115
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2028-07
- **Final completion:** 2030-12
- **Target enrollment:** 699 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187115, "A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07187115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*